drugset
drugset / Trial / NCT05517226

Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

NCT05517226 ↗

Phase 1 Terminated 24 enrolled AstraZeneca Parexel · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the pharmacokinetics (PK), safety, and tolerability of a single subcutaneous injection of cotadutide in participants with mild, moderate or severe hepatic impairment compared to participants with normal hepatic function.

Timeline

Start
2022-09-06
Primary completion
2023-02-27
Completion
2023-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Cotadutide Peptide 50 ug Subcutaneous

Indications

No indication recorded.